Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23975837 | 0.79 | KDM4E (0.45) | ALDH1A1MEN1KMT2AKDM4EMETAP2 | |
| SCHEMBL23976261 | 0.78 | METAP2 (0.44) | ALDH1A1MEN1KMT2AKDM4EMETAP2 | |
| SCHEMBL23975886 | 0.76 | KDM4E (0.48) | ALDH1A1MEN1KMT2AKDM4EMETAP2 | |
| SCHEMBL23991552 | 0.76 | KDM4E (0.46) | ALDH1A1MEN1KMT2AKDM4EMETAP2 | |
| SCHEMBL23976260 | 0.75 | KDM4E (0.46) | ALDH1A1MEN1KMT2AKDM4EMETAP2 | |
| SCHEMBL23976691 | 0.74 | KDM4E (0.41) | ALDH1A1MEN1KMT2AKDM4EMETAP2 | |
| SCHEMBL23975881 | 0.73 | LMNA (0.45) | ALDH1A1MEN1KMT2AKDM4EPDE10A | |
| SCHEMBL23975855 | 0.73 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AKDM4EMETAP2 | |
| SCHEMBL23976561 | 0.70 | NOTUM (0.50) | ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL25934447 | 0.69 | KDM4E (0.40) | ALDH1A1KDM4EMETAP2METAP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12559502-B2 | Thieno pyrimidines as ferroportin inhibitors | Global Blood Therapeutics, Inc (US) | 2026-02-24 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4142732-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4143197-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222483-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222483-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222359-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | ALDH1A1 918/4885MEN1 2863/4885KMT2A 4375/4885 |
| US-20230159553-A1 | THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | ALDH1A1 1007/4885MEN1 2574/4885KMT2A 4433/4885 |
| US-12559502-B2 | Thieno pyrimidines as ferroportin inhibitors | HAMP, TFRC, SLC40A1 | ALDH1A1 898/4885MEN1 2274/4885KMT2A 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.